This review will summarize recent research findings and discuss the therapeutic potential of selected NRs in acute and chronic myeloid leukemia, focusing on RAR, VDR, PPAR, and retinoid X receptor (RXR). Here, RARA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.